drugset / Trial / NCT02504801

Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD

NCT02504801

Phase 4 Unknown 73 enrolled Xiuyi Zhi
RandomizedParallel-groupSingle-blindPrevention

Summary

To test the hypothesis that nebulized Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two treatment arms among primary lung cancer patients with COPD required single lobectomy from 3days before operation to 7 days after operation.

Timeline

Start
2015-07
Primary completion
2016-07
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 2 mg Other